Yersinia spp. is currently an antibiotic resistance concern and a re-emerging disease.
Pharmacometrics and the transition to model-based development
As the transition to model-based drug development continues, pharmacometric analysis will have an increasingly important role across the entire life cycle of drug discovery...
Simulations Plus Releases Unique Dna Mutation Predictor
New Software Screening Tool Helps Pharmaceutical Chemists Predict Drug-Caused DNA Mutations
Simulations Plus Releases Admet Predictor™ Version 2.3
Predictive Accuracy and User Convenience of Best-in-Class Software Now Further Improved
Effect of Formulation on Adinazolam Pharmacokinetics and Pharmacodynamics
Adinazolam has been reported to have anxiolytic and antidepressant properties [1]. Numerous pharmacokinetic (PK) and pharmacodynamic (PD) studies of immediate release as well as sustained release…
Designing In Vitro Dissolution Tests to Better Mimic In Vivo Release
In vitro dissolution tests were traditionally designed for quality control. USP methods commonly used to evaluate the release rate of new controlled release dosage forms are often based on such experiments.
Simulations Plus Reports Third Quarter FY2007 Financial Results
Third Quarter Surpasses Previous Record in Second Quarter
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus.
Simulations Plus Announces Third Quarter Fiscal Year 2007 Earnings Conference Call
Conference Call to be on Thursday, July 5, at 4:15 PM EDT
Simulations Plus Wins Small Business Innovation Research (SBIR) Grant
Grant Funds to Speed Commercialization of Improvements to Company's Industry-Leading Molecular Property Prediction Software
The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process
The current implementation of a pharmacometric process has, in most cases, grown from the ad hoc application of modeling and simulation activities to the drug-development process. This ad hoc…
Mechanism-Based Pharmacokinetic / Pharmacodynamic Model for Hepatoprotective Effect of Dexamethasone on Transient Transaminitis After Trabectedin (ET-743, Yondelis®) Treatment
Reversible transient elevations in transaminases have been observed after trabectedin (T) administration, despite no alteration in plasma PK. A PKPD model was developed to evaluate the time course of ALT elevation…
Population pharmacokinetics of tigecycline in healthy volunteers
Tigecycline, a novel glycylcycline, possesses broad-spectrum antimicrobial activity. A structural population pharmacokinetic model for tigecycline...
Simulations Plus Announces Second Quarter Fiscal Year 2007 Earnings Conference Call
Conference Call to be on Wednesday, April 25, at 4:15 PM EDT
Simulations Plus Reports Second Quarter FY2007 Financial Results
First Six Months' Revenues up 73% and Earnings Jump 1384%
Simulations Plus Extends Its Software Product Line Into Molecular Drug Design
Unique Computer Aided Drug Design Capability Added To Company's ClassPharmer™ Software
The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools
The aim of this study was to assess a physiologically based modeling approach for predicting drug metabolism, tissue distribution, and bioavailability in rat for a structurally diverse set of...
Population pharmacokinetic model for gatifloxacin in pediatric patients
The broad spectrum of antimicrobial activity, oral bioavailability, extensive tissue distribution, and once-daily intravenous or oral dosing of gatifloxacin...